title: Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.
abstract: Morphine conjugate vaccines have effectively reduced behavioral effects of heroin in rodents and primates. To better understand how these effects are mediated, heroin and metabolite distribution studies were performed in rats in the presence and absence of vaccination. In non-vaccinated rats 6-monoacetylmorphine (6-MAM) was the predominant opioid in plasma and brain as early as 1 minute after i.v. administration of heroin and for up to 14 minutes. Vaccination with morphine conjugated to keyhole limpet hemocyanin (M-KLH) elicited high titers and concentrations of antibodies with high affinity for heroin, 6-MAM, and morphine. Four minutes after heroin administration vaccinated rats showed substantial retention of all three opioids in plasma compared to controls and reduced 6-MAM and morphine, but not heroin, distribution to brain. Administration of 6-MAM rather than heroin in M-KLH vaccinated rats showed a similar drug distribution pattern. Vaccination reduced heroin-induced analgesia and blocked heroin-induced locomotor activity throughout 2 weeks of repeated testing. Higher serum opioid-specific antibody concentrations were associated with higher plasma opioid concentrations, lower brain 6-MAM and morphine concentrations, and lower heroin-induced locomotor activity. Serum antibody concentrations over 0.2 mg/ml were associated with substantial effects on these measures. These data support a critical role for 6-MAM in mediating the early effects of i.v. heroin and suggest that reducing 6-MAM concentration in brain is essential to the efficacy of morphine conjugate vaccines.
authors.affiliation: Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA. rale0011@umn.edu
authors.forename: M D
authors.initials: MD
authors.lastname: Raleigh
authors.forename: M
authors.initials: M
authors.lastname: Pravetoni
authors.forename: A C
authors.initials: AC
authors.lastname: Harris
authors.forename: A K
authors.initials: AK
authors.lastname: Birnbaum
authors.forename: P R
authors.initials: PR
authors.lastname: Pentel
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000906:Antibodies / Q000097:blood; D001522:Behavior, Animal / Q000187:drug effects*; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D006433:Hemocyanins / Q000276:immunology; D003932:Heroin / Q000009:adverse effects / Q000276:immunology / Q000493:pharmacokinetics; D007275:Injections, Intravenous; D008297:Male; D009020:Morphine / Q000097:blood / Q000276:immunology* / Q000493:pharmacokinetics; D009022:Morphine Derivatives / Q000097:blood / Q000276:immunology / Q000378:metabolism; D009043:Motor Activity / Q000187:drug effects; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014018:Tissue Distribution; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D009022:Morphine Derivatives; D018074:Vaccines, Conjugate; D003932:Heroin; D009020:Morphine; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin; C026979:6-O-monoacetylmorphine